Last reviewed · How we verify
amorolfine nail lacquer
Amorolfine nail lacquer works by inhibiting the growth of fungi on the nail plate and nail bed.
Amorolfine nail lacquer works by inhibiting the growth of fungi on the nail plate and nail bed. Used for Treatment of onychomycosis (fungal infection of the nails).
At a glance
| Generic name | amorolfine nail lacquer |
|---|---|
| Sponsor | Novartis |
| Drug class | Antifungal |
| Target | Ergosterol synthesis |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It does this by interfering with the synthesis of ergosterol, an essential component of fungal cell membranes. This leads to the death of the fungal cells, effectively treating fungal infections of the nails.
Approved indications
- Treatment of onychomycosis (fungal infection of the nails)
Common side effects
- Skin irritation
Key clinical trials
- Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis (PHASE4)
- Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer (PHASE4)
- Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% (PHASE4)
- Effectiveness of Podiatry Care on Onychomycosis (EPOCAON) (NA)
- Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment (NA)
- Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis (PHASE4)
- A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis (NA)
- Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amorolfine nail lacquer CI brief — competitive landscape report
- amorolfine nail lacquer updates RSS · CI watch RSS
- Novartis portfolio CI